HOOK earnings

Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of careCompany will host a conference call at 4:15 p.m. ET today NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- H

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m. ET on Thursday, April 25, 2024, to highlight path to potential registration; participant details below NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDA

NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight o

NEW YORK and VIENNA, Austria, Aug. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its second quarter 2023 financial results and business highlights on August 10, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight o

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or pre

NEW YORK and VIENNA, March 08, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2022 financial results before the market opens on Wednesday, March 15, 2023. The Company will host a live conference call and webcast at 8:30 AM ET to discuss its financial results and provide a corporate update. Conference Call & Webcast:    Date:  March 15, 2023Time:  8:30 AM ETUSA Dial In:  +1-800-715-9871UK Dial In:  0800-260-6466Austria Dial In:  +43 800-070-441Conference ID:  7669853Webcast:  Link The webcast and

NEW YORK and VIENNA, Austria, Nov. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced it will release its third quarter 2022 financial results and Company update before the market opens on Monday, November 14, 2022. The company will not be conducting a conference call in conjunction with this earnings release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T ce

NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it will release its second quarter 2022 financial results and Company update before the market open on Thursday, August 11, 2022. The Company will not be conducting a conference call in conjunction with this earnings release.About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T c

NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022. The Company will not be conducting a conference call in conjunction with this earnings release.About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or pr

Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patientsHOOKIPA received FDA Fast Track designation and advanced HB-200 to Phase 2 trial in combination with pembrolizumab, with data anticipated in H2 2022HOOKIPA and Gilead agreed to advance partnered HIV program, triggering $54 million commitment from GileadStrong 2021 year-end pro forma cash position of $156.9 million when giving effect to payments received in Q1 2022 from Gilead transaction and proceeds of $75 million public follow-on offering NEW YORK and VIENNA, Austria, March 24, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma I

NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2021 financial results before the market opens on Thursday, March 24, 2022. The Company will host a live conference call and webcast at 8:30 AM ET to discuss its financial results and provide a corporate update. Conference Call & Webcast: Date:March 24, 2022Time:8:30 AM ETUSA Dial In:+1 877 870 9135UK Dial In:0800 279 6619Austria Dial In:+43 (0)1 928 4090Conference ID:1868118Webcast:Link The webcast and the presen

Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combination with pembrolizumab in 1st and 2nd line head and neck cancerInterim Phase 1 HB-200 data continue to show high levels of tumor-specific CD8+ T cells, promising early anti-tumor activity (including 75 percent disease control rate, three partial responses and one near partial response), and a favorable tolerability profile in advanced head and neck cancerHOOKIPA advancing immuno-oncology pipeline across numerous cancers, including HB-300 for prostate cancer and HB-700 for KRAS-mutated cancers, and evaluating combinations of HB-200 with other oncology treatment modalitiesInterim Phase 2 HB-101

NEW YORK and VIENNA, Austria, Nov. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release third quarter 2021 financial results before the market opens on Wednesday, November 10, 2021. The Company will not be conducting a conference call in conjunction with this earnings release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system. HOOKIPA's proprietary arenavir

NEW YORK and VIENNA, Austria, Aug. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release second quarter 2021 financial results and recent highlights before the market opens on Thursday, August 12, 2021. The Company will not be conducting a conference call in conjunction with this earnings release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies that mobilize and amplify targeted T cells and antibodies, the body's natural infection killers, to

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV diseaseObserved CMV-neutralizing antibody responses and tolerability profile are consistent with previous interim resultsCMV can cause severe complications in kidney transplant recipients including organ rejection and death NEW YORK and VIENNA, Austria, Nov. 30, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive interim efficacy results, as well as addi